Abstract
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with intravenous muramyl tripeptide phosphatidylethanolamine (MTP/PE) at a dose of 4 mg once weekly in 20 patients with metastatic soft tissue sarcomas. Responses were not seen in 19 evaluable patients. Toxicity consisted mainly of a mild flu-like syndrome after 62% of drug administrations. It is concluded that MTP/PE at this dose and schedule has no activity in metastatic soft tissue sarcoma.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Acetylmuramyl-Alanyl-Isoglutamine / administration & dosage
-
Acetylmuramyl-Alanyl-Isoglutamine / adverse effects
-
Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives*
-
Acetylmuramyl-Alanyl-Isoglutamine / therapeutic use
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Drug Carriers
-
Female
-
Humans
-
Liposomes
-
Male
-
Middle Aged
-
Phosphatidylethanolamines / administration & dosage*
-
Phosphatidylethanolamines / adverse effects
-
Phosphatidylethanolamines / therapeutic use
-
Sarcoma / drug therapy*
-
Sarcoma / secondary
-
Soft Tissue Neoplasms / drug therapy*
Substances
-
Antineoplastic Agents
-
Drug Carriers
-
Liposomes
-
Phosphatidylethanolamines
-
mifamurtide
-
Acetylmuramyl-Alanyl-Isoglutamine